• 1

    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277300.

  • 2

    Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92:12401251.

    • Search Google Scholar
    • Export Citation
  • 3

    Rappaport H. Tumors of the hematopoietic system. In: Atlas of Tumor Pathology Series (ed I). Washington, DC: Armed Forces Institute of Pathology; 1966.

    • Search Google Scholar
    • Export Citation
  • 4

    Hicks EB, Rappaport H, Winter WJ. Follicular lymphoma; a reevaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 1956;9:792821.

    • Search Google Scholar
    • Export Citation
  • 5

    Bennetta MH, Farrer-Brown G, Henry K. Classification of non-Hodgkin’s lymphomas. Lancet 1974;2:405408.

  • 6

    Lennert K. Malignant lymphomas other than Hodgkin’s disease. New York: Springer-Verlag; 1978.

  • 7

    Lennert K, Feller A. Histopathology of non-Hodgkin’s lymphomas, 2nd ed. Berlin, Germany: Springer-Verlag; 1992.

  • 8

    National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer 1982;49:21122135.

    • Search Google Scholar
    • Export Citation
  • 9

    Classification of non-Hodgkin’s lymphomas. Reproducibility of major classification systems. NCI non-Hodgkin’s Classification Project Writing Committee. Cancer 1985;55:9195.

    • Search Google Scholar
    • Export Citation
  • 10

    Harris NL, Jaffe ES, Stein H. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:13611392.

    • Search Google Scholar
    • Export Citation
  • 11

    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:39093918.

    • Search Google Scholar
    • Export Citation
  • 12

    Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998;16:27802795.

    • Search Google Scholar
    • Export Citation
  • 13

    Harris NL, Jaffe ES, Diebold J. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:38353849.

    • Search Google Scholar
    • Export Citation
  • 14

    Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2001.

    • Search Google Scholar
    • Export Citation
  • 15

    Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:41244130.

    • Search Google Scholar
    • Export Citation
  • 16

    Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008;112:43844399.

    • Search Google Scholar
    • Export Citation
  • 17

    Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008.

  • 18

    Cheson BD, Horning SJ, Coiffier B. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999;17:12441253.

    • Search Google Scholar
    • Export Citation
  • 19

    Cheson BD, Pfistner B, Juweid ME. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579586.

  • 20

    Hehn ST, Grogan TM, Miller TP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 2004;22:30463052.

  • 21

    Meda BA, Buss DH, Woodruff RD. Diagnosis and subclassification of primary and recurrent lymphoma. The usefulness and limitations of combined fine-needle aspiration cytomorphology and flow cytometry. Am J Clin Pathol 2000;113:688699.

    • Search Google Scholar
    • Export Citation
  • 22

    Dong HY, Harris NL, Preffer FI, Pitman MB. Fine-needle aspiration biopsy in the diagnosis and classification of primary and recurrent lymphoma: a retrospective analysis of the utility of cytomorphology and flow cytometry. Mod Pathol 2001;14:472481.

    • Search Google Scholar
    • Export Citation
  • 23

    Jeffers MD, Milton J, Herriot R, McKean M. Fine needle aspiration cytology in the investigation on non-Hodgkin’s lymphoma. J Clin Pathol 1998;51:189196.

    • Search Google Scholar
    • Export Citation
  • 24

    Zeppa P, Marino G, Troncone G. Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-Hodgkin lymphoma: a critical review of 307 cases with technical suggestions. Cancer 2004;102:5565.

    • Search Google Scholar
    • Export Citation
  • 25

    Dunphy CH. Applications of flow cytometry and immunohistochemistry to diagnostic hematopathology. Arch Pathol Lab Med 2004;128:10041022.

    • Search Google Scholar
    • Export Citation
  • 26

    Howell SJ, Shalet SM. Fertility preservation and management of gonadal failure associated with lymphoma therapy. Curr Oncol Rep 2002;4:443452.

    • Search Google Scholar
    • Export Citation
  • 27

    Conlan MG, Bast M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin’s lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990;8:11631172.

    • Search Google Scholar
    • Export Citation
  • 28

    Lim ST, Tao M, Cheung YB. Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy? Ann Oncol 2005;16:215218.

    • Search Google Scholar
    • Export Citation
  • 29

    Kim YH, Willemze R, Pimpinelli N. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:479484.

    • Search Google Scholar
    • Export Citation
  • 30

    Senff N, Kluin-Nelemans H, Willemze R. Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. Br J Haematol 2008;142:5256.

    • Search Google Scholar
    • Export Citation
  • 31

    Juneja SK, Wolf MM, Cooper IA. Value of bilateral bone marrow biopsy specimens in non-Hodgkin’s lymphoma. J Clin Pathol 1990;43:630632.

  • 32

    Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007;110:35073516.

  • 33

    Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005;104:10661074.

    • Search Google Scholar
    • Export Citation
  • 34

    Trotman J, Fournier M, Lamy T. Result of FDG PET-CT imaging after immunochemotherapy induction is a powerful and independent prognostic indicator of outcome for patients with follicular lymphoma: an analysis from the PRIMA study [abstract]. Blood 2010;116:Abstract 855.

    • Search Google Scholar
    • Export Citation
  • 35

    Feeney J, Horwitz S, Gonen M, Schoder H. Characterization of T-cell lymphomas by FDG PET/CT. AJR Am J Roentgenol 2010;195:333340.

  • 36

    Hoffmann M, Kletter K, Becherer A. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003;64:336340.

    • Search Google Scholar
    • Export Citation
  • 37

    Rodriguez-Vigil B, Gomez-Leon N, Pinilla I. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 2006;47:16431648.

    • Search Google Scholar
    • Export Citation
  • 38

    Schaefer NG, Hany TF, Taverna C. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging—do we need contrast-enhanced CT? Radiology 2004;232:823829.

    • Search Google Scholar
    • Export Citation
  • 39

    Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008;2:152162.

  • 40

    Ludwig E, Mendelsohn RB, Taur Y. Prevalence of hepatitis B surface antigen and hepatitis B core antibody in a population initiating immunosuppressive therapy [abstract]. J Clin Oncol 2010;28:Abstract 9009.

    • Search Google Scholar
    • Export Citation
  • 41

    Hwang J, Fisch M, Zhang H. Hepatitis B screening and positivity prior to chemotherapy [abstract]. J Clin Oncol 2010;28:Abstract 9008.

  • 42

    Lok AS, Liang RH, Chiu EK. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182188.

    • Search Google Scholar
    • Export Citation
  • 43

    Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699712.

    • Search Google Scholar
    • Export Citation
  • 44

    Yeo W, Chan PK, Zhong S. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299307.

    • Search Google Scholar
    • Export Citation
  • 45

    Targhetta C, Cabras MG, Mamusa AM. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008;93:951952.

    • Search Google Scholar
    • Export Citation
  • 46

    Loomba R, Rowley A, Wesley R. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519528.

    • Search Google Scholar
    • Export Citation
  • 47

    Tsutsumi Y, Kawamura T, Saitoh S. Hepatitis B virus reactivation in a case of non-Hodgkin’s lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004;45:627629.

    • Search Google Scholar
    • Export Citation
  • 48

    Tsutsumi Y, Tanaka J, Kawamura T. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin’s lymphoma. Ann Hematol 2004;83:5860.

    • Search Google Scholar
    • Export Citation
  • 49

    Lau GK, Yiu HH, Fong DY. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:17421749.

    • Search Google Scholar
    • Export Citation
  • 50

    Carson KR, Evens AM, Richey EA. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:48344840.

    • Search Google Scholar
    • Export Citation
  • 51

    Coiffier B, Altman A, Pui CH. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008;26:27672778.

    • Search Google Scholar
    • Export Citation
  • 52

    Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:311.

  • 53

    Krakoff IH, Meyer RL. Prevention of hyperuricemia in leukemia and lymphoma: use of alopurinol, a xanthine oxidase inhibitor. JAMA 1965;193:16.

    • Search Google Scholar
    • Export Citation
  • 54

    Bosly A, Sonet A, Pinkerton CR. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003;98:10481054.

    • Search Google Scholar
    • Export Citation
  • 55

    Coiffier B, Mounier N, Bologna S. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003;21:44024406.

    • Search Google Scholar
    • Export Citation
  • 56

    Cortes J, Moore JO, Maziarz RT. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study. J Clin Oncol 2010;28:42074213.

    • Search Google Scholar
    • Export Citation
  • 57

    Tsimberidou AM, Wen S, O’Brien S. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2007;25:46484656.

    • Search Google Scholar
    • Export Citation
  • 58

    Dohner H, Stilgenbauer S, Benner A. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:19101916.

  • 59

    Neilson JR, Auer R, White D. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia 1997;11:19291932.

    • Search Google Scholar
    • Export Citation
  • 60

    Austen B, Skowronska A, Baker C. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25:54485457.

    • Search Google Scholar
    • Export Citation
  • 61

    Tsimberidou AM, Tam C, Abruzzo LV. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009;115:373380.

    • Search Google Scholar
    • Export Citation
  • 62

    Rossi D, Cerri M, Deambrogi C. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:9951004.

    • Search Google Scholar
    • Export Citation
  • 63

    Zenz T, Mohr J, Edelmann J. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma 2009;50:510513.

    • Search Google Scholar
    • Export Citation
  • 64

    Tam CS, Shanafelt TD, Wierda WG. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 2009;114:957964.

    • Search Google Scholar
    • Export Citation
  • 65

    Zenz T, Krober A, Scherer K. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008;112:33223329.

    • Search Google Scholar
    • Export Citation
  • 66

    Zenz T, Eichhorst B, Busch R. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:44734479.

  • 67

    Zenz T, Hoth P, Busch R. TP53 mutations and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial of the GCLLSG [abstract]. Blood 2009;114:Abstract 1267.

    • Search Google Scholar
    • Export Citation
  • 68

    Byrd JC, Gribben JG, Peterson BL. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006;24:437443.

    • Search Google Scholar
    • Export Citation
  • 69

    Grever MR, Lucas DM, Dewald GW. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup phase III trial E2997. J Clin Oncol 2007;25:799804.

    • Search Google Scholar
    • Export Citation
  • 70

    Catovsky D, Richards S, Matutes E. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230239.

    • Search Google Scholar
    • Export Citation
  • 71

    Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008;22:211219.

  • 72

    Tsimberidou AM, Tam C, Wierda W. Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl) [abstract]. J Clin Oncol 2007;25:Abstract 7034.

    • Search Google Scholar
    • Export Citation
  • 73

    Hamblin TJ, Davis Z, Gardiner A. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:18481854.

    • Search Google Scholar
    • Export Citation
  • 74

    Hamblin TJ, Davis ZA, Oscier DG. Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia—long-term follow up of patients with different percentages of mutations. Br J Haematol 2008;140:320323.

    • Search Google Scholar
    • Export Citation
  • 75

    Tobin G, Thunberg U, Johnson A. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99:22622264.

    • Search Google Scholar
    • Export Citation
  • 76

    Ghia P, Guida G, Stella S. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003;101:12621269.

    • Search Google Scholar
    • Export Citation
  • 77

    Damle RN, Wasil T, Fais F. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:18401847.

    • Search Google Scholar
    • Export Citation
  • 78

    Thornton PD, Fernandez C, Giustolisi GM. CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol J 2004;5:145151.

    • Search Google Scholar
    • Export Citation
  • 79

    Del Principe MI, Del Poeta G, Buccisano F. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006;108:853861.

    • Search Google Scholar
    • Export Citation
  • 80

    Rassenti LZ, Huynh L, Toy TL. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893901.

    • Search Google Scholar
    • Export Citation
  • 81

    Wiestner A, Rosenwald A, Barry TS. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:49444951.

    • Search Google Scholar
    • Export Citation
  • 82

    Crespo M, Bosch F, Villamor N. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:17641775.

    • Search Google Scholar
    • Export Citation
  • 83

    D’Arena G, Tarnani M, Rumi C. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. Am J Hematol 2007;82:787791.

    • Search Google Scholar
    • Export Citation
  • 84

    Del Giudice I, Morilla A, Osuji N. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer 2005;104:21242132.

    • Search Google Scholar
    • Export Citation
  • 85

    Morilla A, Gonzalez de Castro D, Del Giudice I. Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. Leuk Lymphoma 2008;49:21082115.

    • Search Google Scholar
    • Export Citation
  • 86

    Schroers R, Griesinger F, Trumper L. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005;19:750758.

    • Search Google Scholar
    • Export Citation
  • 87

    Wierda W, O’Brien S, Wang X. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007;109:46794685.

    • Search Google Scholar
    • Export Citation
  • 88

    Rai KR, Sawitsky A, Cronkite EP. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219234.

  • 89

    Binet J, Auquier A, Dighiero G. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198206.

    • Search Google Scholar
    • Export Citation
  • 90

    Rawstron AC. Monoclonal B-cell lymphocytosis. Hematology Am Soc Hematol Educ Program 2009:430439.

  • 91

    Rawstron AC, Bennett FL, O’Connor SJ. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008;359:575583.

  • 92

    Dicker F, Schnittger S, Haferlach T. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006;108:31523160.

    • Search Google Scholar
    • Export Citation
  • 93

    Put N, Konings P, Rack K. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosomes Cancer 2009;48:843853.

    • Search Google Scholar
    • Export Citation
  • 94

    Struski S, Gervais C, Helias C. Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities. Leukemia 2009;23:617619.

    • Search Google Scholar
    • Export Citation
  • 95

    Heerema NA, Byrd JC, Cin PD. Karyotype results from CpG oligodeoxynucleotide stimulated chronic lymphocytic leukemia (CLL) cultures are consistent among laboratories: a CLL Research Consortium (CRC) study [abstract]. Blood 2009;114:Abstract 1614.

    • Search Google Scholar
    • Export Citation
  • 96

    Cheson BD, Bennett JM, Grever M. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:49904997.

    • Search Google Scholar
    • Export Citation
  • 97

    Hallek M, Cheson BD, Catovsky D. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:54465456.

    • Search Google Scholar
    • Export Citation
  • 98

    Raphael B, Andersen JW, Silber R. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 1991;9:770776.

    • Search Google Scholar
    • Export Citation
  • 99

    Rai KR, Peterson BL, Appelbaum FR. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:17501757.

    • Search Google Scholar
    • Export Citation
  • 100

    Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:171178.

  • 101

    Leporrier M, Chevret S, Cazin B. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:23192325.

    • Search Google Scholar
    • Export Citation
  • 102

    Flinn IW, Neuberg DS, Grever MR. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007;25:793798.

    • Search Google Scholar
    • Export Citation
  • 103

    Eichhorst BF, Busch R, Hopfinger G. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885891.

    • Search Google Scholar
    • Export Citation
  • 104

    Byrd JC, Peterson BL, Morrison VA. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:614.

    • Search Google Scholar
    • Export Citation
  • 105

    Woyach JA, Ruppert AS, Heerema NA. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB Study 9712. J Clin Oncol 2011;29:13491355.

    • Search Google Scholar
    • Export Citation
  • 106

    Byrd JC, Rai K, Peterson BL. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:4953.

    • Search Google Scholar
    • Export Citation
  • 107

    Keating MJ, O’Brien S, Albitar M. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:40794088.

    • Search Google Scholar
    • Export Citation
  • 108

    Tam CS, O’Brien S, Wierda W. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975980.

    • Search Google Scholar
    • Export Citation
  • 109

    Parikh SA, Wierda WG, Badoux X. Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL) [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract 6519.

    • Search Google Scholar
    • Export Citation
  • 110

    Hallek M, Fischer K, Fingerle-Rowson G. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:11641174.

    • Search Google Scholar
    • Export Citation
  • 111

    Kay NE, Geyer SM, Call TG. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405411.

    • Search Google Scholar
    • Export Citation
  • 112

    Kay NE, Wu W, Kabat B. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer 2010;116:21802187.

    • Search Google Scholar
    • Export Citation
  • 113

    Knauf WU, Lissichkov T, Aldaoud A. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:43784384.

    • Search Google Scholar
    • Export Citation
  • 114

    Knauf WU, Lissitchkov T, Aldaoud A. Bendamustine induces higher remission rates, prolongs progression free survival as well as time to next treatment, and improves overall survival for patients in complete remission without compromising quality of life when compared to chlorambucil in first line treatment of chronic lymphocytic leukemia [abstract]. Blood 2010;116:Abstract 2449.

    • Search Google Scholar
    • Export Citation
  • 115

    Fischer K, Cramer P, Stilgenbauer S. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract]. Blood 2009;114:Abstract 205.

    • Search Google Scholar
    • Export Citation
  • 116

    Lundin J, Kimby E, Bjorkholm M. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768773.

    • Search Google Scholar
    • Export Citation
  • 117

    Hillmen P, Skotnicki AB, Robak T. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:56165623.

    • Search Google Scholar
    • Export Citation
  • 118

    Wierda W, O’Brien S, Wen S. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:40704078.

    • Search Google Scholar
    • Export Citation
  • 119

    Robak T, Dmoszynska A, Solal-Celigny P. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:17561765.

    • Search Google Scholar
    • Export Citation
  • 120

    Lamanna N, Kalaycio M, Maslak P. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006;24:15751581.

    • Search Google Scholar
    • Export Citation
  • 121

    Weiss MA, Maslak PG, Jurcic JG. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 2003;21:12781284.

    • Search Google Scholar
    • Export Citation
  • 122

    Tsimberidou AM, Wierda WG, Plunkett W. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008;26:196203.

    • Search Google Scholar
    • Export Citation
  • 123

    Tsimberidou AM, Wierda WG, Wen S. Results of a phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in patients with aggressive, relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome (RS) [abstract]. Blood 2010;116:Abstract 923.

    • Search Google Scholar
    • Export Citation
  • 124

    Fischer K, Stilgenbauer S, Schweighofer CD. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG) [abstract]. Blood 2008;112:Abstract 330.

    • Search Google Scholar
    • Export Citation
  • 125

    Bowen DA, Call TG, Jenkins GD. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007;48:24122417.

    • Search Google Scholar
    • Export Citation
  • 126

    Castro JE, James DF, Sandoval-Sus JD. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009;23:17791789.

    • Search Google Scholar
    • Export Citation
  • 127

    Dungarwalla M, Evans SO, Riley U. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008;93:475476.

    • Search Google Scholar
    • Export Citation
  • 128

    Keating MJ, Flinn I, Jain V. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:35543561.

    • Search Google Scholar
    • Export Citation
  • 129

    Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002;347:452453.

    • Search Google Scholar
    • Export Citation
  • 130

    Lozanski G, Heerema NA, Flinn IW. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:32783281.

    • Search Google Scholar
    • Export Citation
  • 131

    Osuji NC, Del Giudice I, Matutes E. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005;90:14351436.

    • Search Google Scholar
    • Export Citation
  • 132

    Cortelezzi A, Pasquini MC, Sarina B. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with chemotherapy-refractory chronic lymphocytic leukemia. Haematologica 2005;90:410412.

    • Search Google Scholar
    • Export Citation
  • 133

    Karlsson C, Lundin J, Kimby E. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol 2009;144:7885.

    • Search Google Scholar
    • Export Citation
  • 134

    Stilgenbauer S, Zenz T, Winkler D. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:39944001.

    • Search Google Scholar
    • Export Citation
  • 135

    Varghese AM, Sayala HA, Moreton P. Long term survival report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group) [abstract]. Blood 2010;116:Abstract 922.

    • Search Google Scholar
    • Export Citation
  • 136

    Fiegl M, Erdel M, Tinhofer I. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Ann Oncol 2010;21:24102419.

    • Search Google Scholar
    • Export Citation
  • 137

    Elter T, Borchmann P, Schulz H. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005;23:70247031.

    • Search Google Scholar
    • Export Citation
  • 138

    Kennedy B, Rawstron A, Carter C. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002;99:22452247.

    • Search Google Scholar
    • Export Citation
  • 139

    Faderl S, Thomas DA, O’Brien S. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:34133415.

    • Search Google Scholar
    • Export Citation
  • 140

    Nabhan C, Patton D, Gordon L. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004;45:22692273.

    • Search Google Scholar
    • Export Citation
  • 141

    Badoux XC, Keating M, O’Brien S. Chemoimmunotherapy with cyclophosphomide, fludarabine, alemtuzumab and rituximab (cfar) is effective in relapsed patients with chronic lymphocytic leukemia (CLL) [abstract]. Blood 2009;114:Abstract 3431.

    • Search Google Scholar
    • Export Citation
  • 142

    Coiffier B, Lepretre S, Pedersen LM. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:10941100.

    • Search Google Scholar
    • Export Citation
  • 143

    Wierda WG, Kipps TJ, Mayer J. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:17491755.

    • Search Google Scholar
    • Export Citation
  • 144

    Wierda WG, Kipps TJ, Mayer J. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Blood 2010;116:Abstract 921.

    • Search Google Scholar
    • Export Citation
  • 145

    Gribben JG, Zahrieh D, Stephans K. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005;106:43894396.

    • Search Google Scholar
    • Export Citation
  • 146

    Khouri IF, Keating MJ, Saliba RM, Champlin RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 2002;4:217221.

    • Search Google Scholar
    • Export Citation
  • 147

    Sorror ML, Storer BE, Sandmaier BM. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008;26:49124920.

    • Search Google Scholar
    • Export Citation
  • 148

    Khouri IF, Saliba RM, Admirand J. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007;137:355363.

    • Search Google Scholar
    • Export Citation
  • 149

    Moreno C, Villamor N, Colomer D. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005;23:34333438.

    • Search Google Scholar
    • Export Citation
  • 150

    Schetelig J, van Biezen A, Brand R. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008;26:50945100.

    • Search Google Scholar
    • Export Citation
  • 151

    Dreger P, Stilgenbauer S, Boettcher S. Prognostic factors for outcome of nonmyeloablative allogeneic stem cell transplantation (NST) in poor-risk chronic lymphocytic leukemia (CLL): final results from a prospective multicenter trial (GCLLSG CLL3X study) [abstract]. Blood 2008;112:Abstract 565.

    • Search Google Scholar
    • Export Citation
  • 152

    Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009;115:28242836.

  • 153

    Salvi F, Miller MD, Grilli A. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 2008;56:19261931.

    • Search Google Scholar
    • Export Citation
  • 154

    Reynolds C, Di Bella N, Lyons RM. Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Blood 2008;112:Abstract 327.

    • Search Google Scholar
    • Export Citation
  • 155

    Keating MJ, Wierda WG, Tam CS. Long term outcome following treatment failure of FCR chemoimmunotherapy as initial therapy for chronic lymphocytic leukemia [abstract]. Blood 2009;114:Abstract 2381.

    • Search Google Scholar
    • Export Citation
  • 156

    Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol 2009;27:110.

  • 157

    Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005;103:216228.

  • 158

    Tsimberidou AM, O’Brien S, Kantarjian HM. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 2006;107:12941302.

    • Search Google Scholar
    • Export Citation
  • 159

    Tsimberidou AM, O’Brien S, Khouri I. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006;24:23432351.

    • Search Google Scholar
    • Export Citation
  • 160

    Rodriguez J, Keating MJ, O’Brien S. Allogeneic haematopoietic transplantation for Richter’s syndrome. Br J Haematol 2000;110:897899.

  • 161

    Tsimberidou AM, Kantarjian HM, Cortes J. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003;97:17111720.

    • Search Google Scholar
    • Export Citation
  • 162

    Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol 2010;23:145153.

    • Search Google Scholar
    • Export Citation
  • 163

    Tsai HT, Caporaso NE, Kyle RA. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood 2009;114:49284932.

    • Search Google Scholar
    • Export Citation
  • 164

    Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma. Cancer 2002;94:20332039.

    • Search Google Scholar
    • Export Citation
  • 165

    Chapel H, Dicato M, Gamm H. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol 1994;88:209212.

    • Search Google Scholar
    • Export Citation
  • 166

    Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med 1988;319:902907.

    • Search Google Scholar
    • Export Citation
  • 167

    Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol 1995;17:7580.

    • Search Google Scholar
    • Export Citation
  • 168

    Molica S, Musto P, Chiurazzi F. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 1996;81:121126.

    • Search Google Scholar
    • Export Citation
  • 169

    Raanani P, Gafter-Gvili A, Paul M. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma 2009;50:764772.

    • Search Google Scholar
    • Export Citation
  • 170

    Sinisalo M, Vilpo J, Itala M. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine 2007;26:8287.

    • Search Google Scholar
    • Export Citation
  • 171

    Sinisalo M, Aittoniemi J, Kayhty H, Vilpo J. Vaccination against infections in chronic lymphocytic leukemia. Leuk Lymphoma 2003;44:649652.

  • 172

    Van der Velden AM, Van Velzen-Blad H, Claessen AM. The effect of ranitidine on antibody responses to polysaccharide vaccines in patients with B-cell chronic lymphocytic leukaemia. Eur J Haematol 2007;79:4752.

    • Search Google Scholar
    • Export Citation
  • 173

    Jurlander J, de Nully Brown P, Skov PS. Improved vaccination response during ranitidine treatment, and increased plasma histamine concentrations, in patients with B cell chronic lymphocytic leukemia. Leukemia 1995;9:19021909.

    • Search Google Scholar
    • Export Citation
  • 174

    Nguyen DD, Cao TM, Dugan K. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 2002;3:105110.

    • Search Google Scholar
    • Export Citation
  • 175

    Laurenti L, Piccioni P, Cattani P. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004;89:12481252.

    • Search Google Scholar
    • Export Citation
  • 176

    Visani G, Mele A, Guiducci B. An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab. Leuk Lymphoma 2006;47:25422546.

    • Search Google Scholar
    • Export Citation
  • 177

    O’Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006;7:125130.

    • Search Google Scholar
    • Export Citation
  • 178

    Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008;2008:450456.

  • 179

    Ding W, Zent CS. Diagnosis and management of autoimmune complications of chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Adv Hematol Oncol 2007;5:257261.

    • Search Google Scholar
    • Export Citation
  • 180

    Borthakur G, O’Brien S, Wierda WG. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab—incidence and predictors. Br J Haematol 2007;136:800805.

    • Search Google Scholar
    • Export Citation
  • 181

    Barcellini W, Capalbo S, Agostinelli R. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica 2006;91:16891692.

    • Search Google Scholar
    • Export Citation
  • 182

    Zanotti R, Frattini F, Ghia P. ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients. Am J Hematol 2010;85:494498.

    • Search Google Scholar
    • Export Citation
  • 183

    Moreno C, Hodgson K, Ferrer G. Autoimmune cytopenias in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 2010;116:47714776.

    • Search Google Scholar
    • Export Citation
  • 184

    Visco C, Ruggeri M, Laura Evangelista M. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008;111:11101116.

    • Search Google Scholar
    • Export Citation
  • 185

    Cortes J, O’Brien S, Loscertales J. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer 2001;92:20162022.

    • Search Google Scholar
    • Export Citation
  • 186

    D’Arena G, Laurenti L, Capalbo S. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006;81:598602.

    • Search Google Scholar
    • Export Citation
  • 187

    Gupta N, Kavuru S, Patel D. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002;16:20922095.

    • Search Google Scholar
    • Export Citation
  • 188

    Berentsen S. Rituximab for the treatment of autoimmune cytopenias. Haematologica 2007;92:15891596.

  • 189

    Godeau B, Porcher R, Fain O. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008;112:9991004.

    • Search Google Scholar
    • Export Citation
  • 190

    Hegde UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002;100:22602262.

    • Search Google Scholar
    • Export Citation
  • 191

    Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003;78:13401346.

    • Search Google Scholar
    • Export Citation
  • 192

    Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood 2002;99:10921094.

    • Search Google Scholar
    • Export Citation
  • 193

    Bussel JB, Kuter DJ, Newland A. Long-term efficacy and safety of romiplostim for the treatment of patients with chronic immune thrombocytopenia (ITP): 5-year update from an open-label extension study [abstract]. Blood 2009;114:Abstract 681.

    • Search Google Scholar
    • Export Citation
  • 194

    Kuter DJ, Bussel JB, Lyons RM. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395403.

    • Search Google Scholar
    • Export Citation
  • 195

    Bussel JB, Cheng G, Saleh MN. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:22372247.

  • 196

    Dearden C, Wade R, Else M. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008;111:18201826.

    • Search Google Scholar
    • Export Citation
  • 197

    Koster A, Tromp HA, Raemaekers JM. The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. Haematologica 2007;92:184190.

    • Search Google Scholar
    • Export Citation
  • 198

    Wang SA, Wang L, Hochberg EP. Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Am J Surg Pathol 2005;29:14901496.

    • Search Google Scholar
    • Export Citation
  • 199

    Hans CP, Weisenburger DD, Vose JM. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003;101:23632367.

    • Search Google Scholar
    • Export Citation
  • 200

    Katzenberger T, Ott G, Klein T. Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. Am J Pathol 2004;165:481490.

    • Search Google Scholar
    • Export Citation
  • 201

    Solal-Celigny P, Roy P, Colombat P. Follicular lymphoma international prognostic index. Blood 2004;104:12581265.

  • 202

    Friedberg JW, Taylor MD, Cerhan JR. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009;27:12021208.

    • Search Google Scholar
    • Export Citation
  • 203

    Federico M, Bellei M, Marcheselli L. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:45554562.

    • Search Google Scholar
    • Export Citation
  • 204

    Schoder H, Noy A, Gonen M. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2005;23:46434651.

    • Search Google Scholar
    • Export Citation
  • 205

    Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004;22:14541459.

    • Search Google Scholar
    • Export Citation
  • 206

    McLaughlin P, Fuller L, Redman J. Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy. Ann Oncol 1991;2(Suppl 2):137140.

    • Search Google Scholar
    • Export Citation
  • 207

    Yahalom J, Varsos G, Fuks Z. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer 1993;71:23422350.

    • Search Google Scholar
    • Export Citation
  • 208

    Colombat P, Salles G, Brousse N. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101106.

    • Search Google Scholar
    • Export Citation
  • 209

    Witzig TE, Vukov AM, Habermann TM. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005;23:11031108.

    • Search Google Scholar
    • Export Citation
  • 210

    McLaughlin P, Grillo-Lopez AJ, Link BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:28252833.

    • Search Google Scholar
    • Export Citation
  • 211

    Schulz H, Bohlius JF, Trelle S. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706714.

    • Search Google Scholar
    • Export Citation
  • 212

    Czuczman MS, Grillo-Lopez AJ, White CA. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268276.

    • Search Google Scholar
    • Export Citation
  • 213

    Czuczman MS, Weaver R, Alkuzweny B. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:47114716.

    • Search Google Scholar
    • Export Citation
  • 214

    Hiddemann W, Kneba M, Dreyling M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:37253732.

    • Search Google Scholar
    • Export Citation
  • 215

    Buske C, Kneba M, Lengfelder E. Front-line combined immuno-chemotherapy (R-CHOP) significantly improves the time to treatment failure and overall survival in elderly patients with advanced stage follicular lymphoma—results of a prospective randomized trial of the german low grade lymphoma study group (GLSG) [abstract]. Blood 2006;108:Abstract 482.

    • Search Google Scholar
    • Export Citation
  • 216

    Marcus R, Imrie K, Belch A. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:14171423.

    • Search Google Scholar
    • Export Citation
  • 217

    Marcus R, Imrie K, Solal-Celigny P. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:45794586.

    • Search Google Scholar
    • Export Citation
  • 218

    Czuczman MS, Koryzna A, Mohr A. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694704.

    • Search Google Scholar
    • Export Citation
  • 219

    Forstpointner R, Dreyling M, Repp R. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:30643071.

    • Search Google Scholar
    • Export Citation
  • 220

    McLaughlin P, Hagemeister FB, Rodriguez MA. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 2000;27:3741.

    • Search Google Scholar
    • Export Citation
  • 221

    Zinzani PL, Pulsoni A, Perrotti A. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004;22:26542661.

    • Search Google Scholar
    • Export Citation
  • 222

    Rummel MJ, Niederle N, Maschmeyer G. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood 2009;114:Abstract 405.

    • Search Google Scholar
    • Export Citation
  • 223

    Friedberg JW, Cohen P, Chen L. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204210.

    • Search Google Scholar
    • Export Citation
  • 224

    Kahl BS, Bartlett NL, Leonard JP. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010;116:106114.

    • Search Google Scholar
    • Export Citation
  • 225

    Robinson KS, Williams ME, van der Jagt RH. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:44734479.

    • Search Google Scholar
    • Export Citation
  • 226

    Rummel MJ, Kaiser U, Balser C. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas - final results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood 2010;116:Abstract 856.

    • Search Google Scholar
    • Export Citation
  • 227

    Kaminski MS, Tuck M, Estes J. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441449.

  • 228

    Vose JM, Wahl RL, Saleh M. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2000;18:13161323.

    • Search Google Scholar
    • Export Citation
  • 229

    Kaminski MS, Zelenetz AD, Press OW. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2001;19:39183928.

    • Search Google Scholar
    • Export Citation
  • 230

    Horning SJ, Younes A, Jain V. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005;23:712719.

    • Search Google Scholar
    • Export Citation
  • 231

    Witzig TE, Flinn IW, Gordon LI. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 2002;20:32623269.

    • Search Google Scholar
    • Export Citation
  • 232

    Witzig TE, Gordon LI, Cabanillas F. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002;20:24532463.

    • Search Google Scholar
    • Export Citation
  • 233

    Gordon LI, Witzig T, Molina A. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004;5:98101.

    • Search Google Scholar
    • Export Citation
  • 234

    Kaminski MS, Tuck M, Estes J. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results [abstract]. Blood 2009;114:Abstract 3759.

    • Search Google Scholar
    • Export Citation
  • 235

    Scholz CW, Pinto A, Linkesch W. 90Yttrium ibritumomab tiuxetan as first line treatment for follicular lymphoma. First results from an international phase II clinical trial [abstract]. Blood 2010;116:Abstract 593.

    • Search Google Scholar
    • Export Citation
  • 236

    Kaminski MS, Zelenetz AD, Press OW. Tositumomab and I 131 tositumomab achieves complete remissions lasting > 10 years in patients with chemotherapy-refractory low-grade and transformed B-cell lymphomas [abstract]. Blood 2010;116:Abstract 3960.

    • Search Google Scholar
    • Export Citation
  • 237

    Young RC, Longo DL, Glatstein E. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988;25:1116.

    • Search Google Scholar
    • Export Citation
  • 238

    Brice P, Bastion Y, Lepage E. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997;15:11101117.

    • Search Google Scholar
    • Export Citation
  • 239

    Ardeshna KM, Smith P, Norton A. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516522.

    • Search Google Scholar
    • Export Citation
  • 240

    Ardeshna KM, Qian W, Smith P. An Intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis [abstract]. Blood 2010;116:Abstract 6.

    • Search Google Scholar
    • Export Citation
  • 241

    Peterson BA, Petroni GR, Frizzera G. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 2003;21:515.

    • Search Google Scholar
    • Export Citation
  • 242

    Leonard JP, Coleman M, Kostakoglu L. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:56965704.

    • Search Google Scholar
    • Export Citation
  • 243

    Press OW, Unger JM, Braziel RM. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:41434149.

    • Search Google Scholar
    • Export Citation
  • 244

    Press OW, Unger JM, Braziel RM. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group protocol S9911. Blood 2003;102:16061612.

    • Search Google Scholar
    • Export Citation
  • 245

    Link BK, Martin P, Kaminski MS. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol 2010;28:30353041.

    • Search Google Scholar
    • Export Citation
  • 246

    Hainsworth JD, Spigel DR, Markus TM. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 2009;9:223228.

    • Search Google Scholar
    • Export Citation
  • 247

    Jacobs SA, Swerdlow SH, Kant J. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008;14:70887094.

    • Search Google Scholar
    • Export Citation
  • 248

    Morschhauser F, Radford J, Van Hoof A. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:51565164.

    • Search Google Scholar
    • Export Citation
  • 249

    Zinzani PL, Tani M, Pulsoni A. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 2008;9:352358.

    • Search Google Scholar
    • Export Citation
  • 250

    Hagenbeek A, Radford J, Van Hoof A. 90Y-ibritumomab tiuxetan (Zevalin(R)) consolidation of first remission in advanced-stage follicular non-hodgkin’s lymphoma: updated results after a median follow-up of 66.2 months from the international, randomized, phase III First-Line Indolent Trial (FIT) in 414 patients [abstract]. Blood 2010;116:Abstract 594.

    • Search Google Scholar
    • Export Citation
  • 251

    Ghielmini M, Schmitz SF, Cogliatti SB. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:44164423.

    • Search Google Scholar
    • Export Citation
  • 252

    Martinelli G, Hsu Schmitz SF, Utiger U. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010;28:44804484.

    • Search Google Scholar
    • Export Citation
  • 253

    Taverna CJ, Bassi S, Hitz F. Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03 [abstract]. Blood 2010;116:Abstract 1802.

    • Search Google Scholar
    • Export Citation
  • 254

    Hainsworth JD, Litchy S, Shaffer DW. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin’s lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:10881095.

    • Search Google Scholar
    • Export Citation
  • 255

    Hochster H, Weller E, Gascoyne RD. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009;27:16071614.

    • Search Google Scholar
    • Export Citation
  • 256

    Salles GA, Seymour JF, Feugier P. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy [abstract]. J Clin Oncol 2010;28:Abstract 8004.

    • Search Google Scholar
    • Export Citation
  • 257

    Salles G, Seymour JF, Offner F. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:4251.

    • Search Google Scholar
    • Export Citation
  • 258

    Forstpointner R, Unterhalt M, Dreyling M. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:40034008.

    • Search Google Scholar
    • Export Citation
  • 259

    van Oers MH, Klasa R, Marcus RE. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:32953301.

    • Search Google Scholar
    • Export Citation
  • 260

    van Oers MH, Van Glabbeke M, Giurgea L. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:28532858.

    • Search Google Scholar
    • Export Citation
  • 261

    Freedman AS, Neuberg D, Mauch P. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:33253333.

    • Search Google Scholar
    • Export Citation
  • 262

    Rohatiner AZ, Nadler L, Davies AJ. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007;25:25542559.

    • Search Google Scholar
    • Export Citation
  • 263

    Schouten HC, Qian W, Kvaloy S. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:39183927.

    • Search Google Scholar
    • Export Citation
  • 264

    Sebban C, Brice P, Delarue R. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008;26:36143620.

    • Search Google Scholar
    • Export Citation
  • 265

    Peniket AJ, Ruiz de Elvira MC, Taghipour G. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003;31:667678.

    • Search Google Scholar
    • Export Citation
  • 266

    van Besien K, Loberiza FR, Bajorunaite R. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003;102:35213529.

    • Search Google Scholar
    • Export Citation
  • 267

    Hari P, Carreras J, Zhang MJ. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008;14:236245.

    • Search Google Scholar
    • Export Citation
  • 268

    Al-Tourah AJ, Chhanabhai M, Hoskins PJ. Transformed lymphoma: incidence and long-term outcome [abstract]. Blood 2004;104:Abstract 3253.

  • 269

    Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995;13:17261733.

    • Search Google Scholar
    • Export Citation
  • 270

    Alizadeh AA, Eisen MB, Davis RE. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503511.

    • Search Google Scholar
    • Export Citation
  • 271

    Hans CP, Weisenburger DD, Greiner TC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275282.

    • Search Google Scholar
    • Export Citation
  • 272

    Choi WWL, Weisenburger DD, Greiner TC. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:54945502.

    • Search Google Scholar
    • Export Citation
  • 273

    A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987994.